Quiros Juan Jose Chacon Sells 67,249 Shares of Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 67,249 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $70.78, for a total transaction of $4,759,884.22. Following the completion of the transaction, the director directly owned 1,040,255 shares of the company’s stock, valued at $73,629,248.90. This represents a 6.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Monday, May 4th, Quiros Juan Jose Chacon sold 7,751 shares of Establishment Labs stock. The stock was sold at an average price of $70.48, for a total transaction of $546,290.48.
• On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The stock was sold at an average price of $66.26, for a total transaction of $144,446.80.
• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The stock was sold at an average price of $65.78, for a total transaction of $1,985,108.84.
• On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The stock was sold at an average price of $65.43, for a total transaction of $2,790,066.06.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total transaction of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75.

Establishment Labs Trading Up 1.1%

Shares of Establishment Labs stock opened at $70.99 on Wednesday. The company has a market capitalization of $2.09 billion, a P/E ratio of -40.80 and a beta of 1.12. The company has a debt-to-equity ratio of 10.51, a quick ratio of 2.00 and a current ratio of 3.04. The company has a fifty day moving average of $65.43 and a 200 day moving average of $66.22. Establishment Labs Holdings Inc. has a fifty-two week low of $32.25 and a fifty-two week high of $83.31.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.13. The company had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. Establishment Labs’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.19) EPS. On average, sell-side analysts anticipate that Establishment Labs Holdings Inc. will post -0.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Sigma Planning Corp lifted its holdings in shares of Establishment Labs by 325.5% in the 1st quarter. Sigma Planning Corp now owns 20,424 shares of the company’s stock valued at $1,160,000 after acquiring an additional 15,624 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new position in shares of Establishment Labs in the 1st quarter valued at about $209,000. Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Establishment Labs by 20.4% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 5,450 shares of the company’s stock valued at $309,000 after acquiring an additional 925 shares during the last quarter. Cannon Global Investment Management LLC bought a new position in shares of Establishment Labs in the 1st quarter valued at about $738,000. Finally, Brian Low Financial Group LLC lifted its holdings in shares of Establishment Labs by 10.2% in the 1st quarter. Brian Low Financial Group LLC now owns 4,598 shares of the company’s stock valued at $261,000 after acquiring an additional 424 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ESTA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Stephens increased their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Wall Street Zen downgraded shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. BTIG Research reissued a “buy” rating and set a $88.00 price objective on shares of Establishment Labs in a report on Wednesday, April 29th. Finally, Needham & Company LLC increased their price objective on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Establishment Labs currently has an average rating of “Moderate Buy” and a consensus price target of $86.86.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.